Bradycor bradykinin antagonist data

CRTQ (Denver) presented a subgroup analysis of its Phase II trial, which had failed to demonstrate an overall statistical difference in the 504 patients.

In the subgoup of 112 patients with gram-negative infection, there was a 19 percent improvement in survival at 28 days (p=0.07) for the 84 patients who received the drug. ...